Vaccine Reaction
Conditions
Brief summary
In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned. Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2)
Detailed description
In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned. Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine (BNT162b2, pfizer) as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2). The antobody IgG RBD levels will be checked before the booster dose and then after 3 weeks of the booster.
Interventions
BIOLOGICALbooster vaccine for COVID 19
The effect of Booster vaccine will be seen in participants in terms of antibody response IgG
Sponsors
Lahore General Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* people who have received two doses of sinopharm or sinovac and six months have passed after the second dose
Exclusion criteria
* people getting one shot of sinopharm or sinovac or got vaccine other than sinopharm and sinovac.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IgG RBD levels | after 3 weeks of booster vaccine dose | to see the effect of booster vaccine after 3 weeks in terms of IgG RBD |
Countries
Pakistan
Outcome results
None listed